Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Abatacept Appears Safe for RA Patients with COPD

Publish date:: April 15, 2019

Key clinical point: Abatacept doesn’t appear to exacerbate COPD in patients with rheumatoid arthritis.

Major finding: Risks for COPD exacerbation, flu, bronchitis, and pneumonia were not significantly elevated versus those with other biologic DMARDs.

Study details: The MarketScan database review comprised 4,634 patients.

Disclosures: Dr. Suissa disclosed relationships with AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, and Novartis.

Citation:

Suissa S et al. Semin Arthritis Rheum. 2019 Mar 16. doi: 10.1016j.semarthrit.2019.03.007.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Pulmonology

E-cigarette use tied to increased COPD, asthma risk,

Obesity, hypoxia predict severity in children with COVID-19,

Telehealth finds acceptance among patients with CF, clinicians,

COVID-19 burdens follow patients after discharge,

Poverty raises depression risk in patients with cystic fibrosis,